Authors

Latest:

Dr. Kubicky on the Optimal Use of Radiation in Patients With Breast Cancer

Charlotte Kubicky, MD, PhD, associate professor of radiation medicine, School of Medicine, medical director, Tuality Oregon Health and Science Cancer Center, Oregon Health and Science University, discusses the optimal use of radiation in the treatment of patients with breast cancer.

Charlton A. Smith, MD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Charu Aggarwal, MD

Latest:

Advancement in NSCLC Precision Medicine: Biomarker Testing

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

Charu Aggarwal, MD, MPH, Hospital of the University of Pennsylvania

Charu Aggarwal, MD, MPH, University of Pennsylvania Hospital

Latest:

Trilaciclib: Treatment Considerations

Advantages associated with the administration of trilaciclib in appropriate patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

Chase Doyle

Latest:

Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard Therapy

According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.

Chau Dang, MD

Latest:

Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

Che-Kai Tsao, MD

Latest:

Dr Tsao on the Role of Nivolumab Plus Cabozantinib in Advanced RCC

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

Chelsea C. Pinnix, MD, PhD

Latest:

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.

Chelsea LoCascio

Latest:

Rugo Covers Scope of Recent Breast Cancer Advances

Hope S. Rugo, MD, discusses a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.

Cheryl Alkon

Latest:

Building Foundations for Understanding Drug Mechanisms in Oncology

A 2018 Giants of Cancer Care award winner for Drug Development, Joseph R. Bertino, MD, was an early pioneer in developing the understanding of methotrexate and its administration in cancer. His work has served as a platform for much broader investigation into the optimal use of other cancer agents. Along the way, Bertino has mentored many leaders in oncology and hematology and earned international recognition.

Cheryl Zigrand

Latest:

Experts Share Hopes for the Future of Myeloma Treatment

The data being amassed about novel multiple myeloma therapies have the potential to change the way patients with relapsed or refractory disease are currently being treated.

Chiara Cremolini, MD

Latest:

Dr Cremolini on the Implications of the TRANSMET Trial in Colorectal Liver Metastases

Chiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.

Ching-Hon Pui, MD

Latest:

Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Chip Landen, MD

Latest:

Dr. Landen Discusses p53 Mutations in Ovarian Cancer

Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the role of p53 mutations in patients with ovarian cancer.

Chirag Shah, MD

Latest:

Dr Shah on Research to Minimize Surgical Intervention in Locoregional Breast Cancer

Chirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.

Chloe E. Atreya, MD, PhD

Latest:

Dr. Atreya Discusses Maintenance Therapy for CRC

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

Chong-Xian Pan, MD, PhD

Latest:

Patient-Derived Xenografts Could Improve Precision Medicine Outcomes

Researchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.

Chris Parker, MD

Latest:

Dr. Parker on the Optimal Timing of Salvage Therapy in Prostate Cancer

Chris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.

Chris Parker, MD, FRCR, MRCP, Institute of Cancer Research, Royal Marsden Hospital